| | 1346704-33-3 Basic information More.. |
| Product Name: | GSK 343 | | Synonyms: | 1H-Indazole-4-carboxamide, N-[(1,2-dihydro-6-methyl-2-oxo-4-propyl-3-pyridinyl)methyl]-1-(1-methylethyl)-6-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-;1-(1-Methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-1H-indazole-4-carboxamide GSK343;GSK 343;GSK343;GSK-343;GSK-343/GSK343;1-(1-Methylethyl)-N-[(6-Methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)Methyl]-6-[2-(4-Methyl-1-piperazinyl)-4-pyridinyl]-1H-indazole-4-carboxaMide;N-[(1,2-Dihydro-6-methyl-2-oxo-4-propyl-3-pyridinyl)methyl]-1-(1-methylethyl)-6-[2-(4-methyl-1-piperazinyl)-4-py | | CAS: | 1346704-33-3 | | MF: | C31H39N7O2 | | MW: | 541.69 | | EINECS: | | | Mol File: | 1346704-33-3.mol |  |
Use
GSK343 inhibits trimethylation of H3K27 (H3K27me3) with IC50 of 174 nM in HCC1806 breast cancer cells. GSK343 potently inhibits cell proliferation in breast cancer cells and prostate cancer cells, and the prostate cancer cell line LNCaP is the most sensitive to GSK343, with IC50 of 2.9 μM. GSK343 significantly suppresses the growth of EOC cells cultured in 3D matrigel extracellular matrix (ECM), which mimics the tumor microenvironment in vivo. In addition, GSK343 also induces apoptosis of EOC cells in 3D and significantly inhibits the invasion of EOC cells.
- GSK 343
-
- US $1.00 / g
- 2020-01-14
- CAS:1346704-33-3
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 200kg
|
|
1346704-33-3
Recommend Suppliers |
|